Search research articles
Contact Us
Filters
Showing results (131-140 of 257) with videos related to
Page
of 26
Sort By:
The British Journal of Dermatology
|
January 25, 2025
Bimekizumab efficacy and safety through 3 years in patients with moderate to severe plaque psoriasis: Long-term results from the BE RADIANT phase 3b trial open-label extension period
Richard B Warren, Mark Lebwohl, Diamant Thaçi, et al.
JAMA Dermatology
|
May 11, 2022
Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials
Kenneth B Gordon, Richard G Langley, Richard B Warren, et al.
Dermatology and Therapy
|
November 22, 2024
Bimekizumab Efficacy in High-Impact Areas: Pooled 2-Year Analysis in Scalp, Nail, and Palmoplantar Psoriasis from Phase 3/3b Randomized Controlled Trials
Joseph F Merola, Alice B Gottlieb, Andreas Pinter, et al.
American Journal of Clinical Dermatology
|
August 31, 2025
Bimekizumab Complete Clearance of Both Skin and Nail Psoriasis: Comparative Efficacy in Phase III/IIIb Studies
Joseph F Merola, Richard B Warren, Diamant Thaçi, et al.
Trials
|
February 12, 2020
A randomised placebo controlled trial of anakinra for treating pustular psoriasis: statistical analysis plan for stage two of the APRICOT trial
Suzie Cro, Prakash Patel, Jonathan Barker, et al.
ACR Open Rheumatology
|
July 30, 2024
Efficacy and Safety of Bimekizumab in Patients With Psoriatic Arthritis With or Without Methotrexate: 52-Week Results From Two Phase 3 Studies
Iain B McInnes, Philip J Mease, Yoshiya Tanaka, et al.
Dermatology and Therapy
|
July 7, 2022
Efficacy of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: A Systematic Literature Review and a Network Meta-Analysis
April Armstrong, Kyle Fahrbach, Craig Leonardi, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
June 26, 2015
Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis
Meghna Jani, Hector Chinoy, Richard B Warren, et al.
Journal of the American Academy of Dermatology
|
December 29, 2016
Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials
Kristian Reich, Craig Leonardi, Richard G Langley, et al.
The Journal of Investigative Dermatology
|
October 22, 2017
Risk of Serious Infection in Patients with Psoriasis Receiving Biologic Therapies: A Prospective Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
Zenas Z N Yiu, Catherine H Smith, Darren M Ashcroft, et al.
Page
of 26
Search research articles
Search
Showing results (131-140 of 257) with videos related to
Sort By:
Page
of 26
The British Journal of Dermatology
|
January 25, 2025
Bimekizumab efficacy and safety through 3 years in patients with moderate to severe plaque psoriasis: Long-term results from the BE RADIANT phase 3b trial open-label extension period
Richard B Warren, Mark Lebwohl, Diamant Thaçi, et al.
JAMA Dermatology
|
May 11, 2022
Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials
Kenneth B Gordon, Richard G Langley, Richard B Warren, et al.
Dermatology and Therapy
|
November 22, 2024
Bimekizumab Efficacy in High-Impact Areas: Pooled 2-Year Analysis in Scalp, Nail, and Palmoplantar Psoriasis from Phase 3/3b Randomized Controlled Trials
Joseph F Merola, Alice B Gottlieb, Andreas Pinter, et al.
American Journal of Clinical Dermatology
|
August 31, 2025
Bimekizumab Complete Clearance of Both Skin and Nail Psoriasis: Comparative Efficacy in Phase III/IIIb Studies
Joseph F Merola, Richard B Warren, Diamant Thaçi, et al.
Trials
|
February 12, 2020
A randomised placebo controlled trial of anakinra for treating pustular psoriasis: statistical analysis plan for stage two of the APRICOT trial
Suzie Cro, Prakash Patel, Jonathan Barker, et al.
ACR Open Rheumatology
|
July 30, 2024
Efficacy and Safety of Bimekizumab in Patients With Psoriatic Arthritis With or Without Methotrexate: 52-Week Results From Two Phase 3 Studies
Iain B McInnes, Philip J Mease, Yoshiya Tanaka, et al.
Dermatology and Therapy
|
July 7, 2022
Efficacy of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: A Systematic Literature Review and a Network Meta-Analysis
April Armstrong, Kyle Fahrbach, Craig Leonardi, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
June 26, 2015
Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis
Meghna Jani, Hector Chinoy, Richard B Warren, et al.
Journal of the American Academy of Dermatology
|
December 29, 2016
Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials
Kristian Reich, Craig Leonardi, Richard G Langley, et al.
The Journal of Investigative Dermatology
|
October 22, 2017
Risk of Serious Infection in Patients with Psoriasis Receiving Biologic Therapies: A Prospective Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
Zenas Z N Yiu, Catherine H Smith, Darren M Ashcroft, et al.
Page
of 26